Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6717235 | 0.93 | MEN1 (0.53) | KMT2AMAPTMEN1CYP2C9CYP2C19 | |
| SCHEMBL6713814 | 0.93 | KMT2A (0.49) | KMT2AMAPTMEN1CYP2C9CYP2C19 | |
| SCHEMBL6716840 | 0.93 | KMT2A (0.49) | KMT2AMAPTMEN1CYP2C9CYP2C19 | |
| SCHEMBL6717161 | 0.90 | ALDH1A1 (0.53) | KMT2AMAPTMEN1CYP2C9CYP2C19 | |
| SCHEMBL6715694 | 0.87 | RAB9A (0.52) | KMT2AMAPTMEN1CYP2C9CYP2C19 | |
| SCHEMBL6717198 | 0.86 | LMNA (0.50) | KMT2AMAPTMEN1CYP2C9CYP2C19 | |
| SCHEMBL6723453 | 0.85 | LMNA (0.48) | KMT2AMAPTMEN1CYP2C9CYP2C19 | |
| SCHEMBL6717589 | 0.85 | MEN1 (0.48) | KMT2AMAPTMEN1CYP2C9CYP2C19 | |
| SCHEMBL6716685 | 0.85 | MAPT (0.52) | KMT2AMAPTMEN1CYP2C9CYP2C19 | |
| SCHEMBL6717497 | 0.84 | KMT2A (0.49) | KMT2AMAPTMEN1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | KMT2A 2020/4885MAPT 427/4885MEN1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.